Art. -Nr.: HY-145723

MAX-40279

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

MAX-40279 is a dual and orally active inhibitor of FLT3 kinase and FGFR kinase. MAX-40279 is also effective against the FLT3 mutants such as FLT3^D835Y, suggesting that it can overcome resistance to Quizartinib (HY-13001) and Sorafenib (HY-10201). MAX-40279 inhibits NDRG1 phosphorylation at Ser330 and suppresses endothelial-to-mesenchymal transition (EndMT). MAX-40279 can be used for the research of acute myelogenous leukemia (AML).

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 97.04%
CAS. Nr.: 2070931-57-4
Formel: C₂₂H₂₃FN₆OS
Molecular Weight:438.52

Speicherung:

Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month

MAX-40279 Chemical Structure

CAS. Nr.: 2070931-57-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

FLT3 and FGFR^[1]

In Vitro

MAX-40279 (0.5-1 μM, 48 h) impedes EndMT by inhibiting NDRG1 phosphorylation at Ser-330 in HUVECs, MAECs, and MPLECs^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Migration Assay ^[3]

Cell Line:

HUVECs
Concentration:

0.5 and 1 μM
Incubation Time:

48 h
Result:

Attenuated migration of HUVEC induced by H₂O₂ and TGF-β.

Western Blot Analysis^[3]

Cell Line:

HUVECs, MAECs, and MPLECs
Concentration:

0.5 and 1 μM
Incubation Time:

48 h
Result:

Significantly inhibited the phosphorylation of NDRG1 at Ser-330.
Reduced the total protein level of NDRG1.
Inhibited the expression of mesenchymal markers such as ZEB1, α-SMA, Slug, Snail, and TAGLN.

In Vivo

MAX-40279 (12 mg/kg, p,o., once daily for 7 days) is effective in 43% of patient tumor samples in mouse Mini-PDX assay^[1].
MAX-40279 (12 mg/kg, p,o., twice daily for 21-28 days) significantly inhibited tumor growth in MV4-11 and KG-1 cells induced mice xenograft models^[1].
MAX-40279 (7-15 mg/kg, p.o., twice daily for 2-3 weeks) significantly enhances the anti-PD-1 therapeutic effect in mice breast cancer model^[1].
MAX-40279 (p.o., single dose) has much higher drug concentration in bone marrow than in plasma in SD rats^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Micro patient-derived xenotransplantation model established in 5-week-old nu/nu mice^[1]
Dosage:

12 mg/kg
Administration:

Oral administration (p.o.), once daily for 7 days
Result:

Reduced the vitality of tumor cells.
The growth rates of tumour volume and weight were smaller but that the combined inhibition was more remarkable.

Animal Model:

MV4-11 and KG-1 cells induced xenograft model established in immunodeficient mice^[1]
Dosage:

12 mg/kg
Administration:

Oral administration (p.o.), twice daily for 21-28 days
Result:

Significantly inhibited tumor growth, with no significant weight loss or toxicity observed.

Animal Model:

4T1 induced breast cancer model combination with anti-PD-1 established in mice^[1]
Dosage:

7, 10 and 15 mg/kg
Administration:

Oral administration (p.o.), twice daily for 2-3 weeks
Result:

Significantly enhanced the efficacy of anti-PD-1 effect, and the combined treatment with anti-PD-1 antibodies yielded the best results.

Chemical Information

CAS. Nr. 2070931-57-4
Appearance Solid
Molecular Weight 438.52
Formel C₂₂H₂₃FN₆OS
Color Off-white to light yellow
SMILES

FC1=CC(OC)=C(C2=C(C)SC3=C2N=C(NC4=CN(C5CCNCC5)N=C4)N=C3)C=C1
Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

Powder	-20°C	3 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Theranostics

PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis. [Abstract]

2025 Jan 1;15(2):745-765. PMID: 39744686

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : ≥ 25 mg/mL (57.01 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.2804 mL

11.4020 mL

22.8040 mL

5 mM

0.4561 mL

2.2804 mL

4.5608 mL

10 mM

0.2280 mL

1.1402 mL

2.2804 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (5.70 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (281 KB)
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Yuguang Wang, et al. Novel Therapeutic Methods. Patent WO2021180032A1.

[2]. Yuguang Wang, et al. Preclinical Evaluation of MAX-40279, a FLT3/FGFR Dual Kinase Inhibitor for Treatment of Acute Myeloid Leukemia, Blood, Volume 132, Supplement 1, 2018.

[3]. Xue Z, et al. PIM1 instigates endothelial-to-mesenchymal transition to aggravate atherosclerosis. Theranostics. 2025 Jan 1;15(2):745-765. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.2804 mL	11.4020 mL	22.8040 mL	57.0099 mL
	5 mM	0.4561 mL	2.2804 mL	4.5608 mL	11.4020 mL
	10 mM	0.2280 mL	1.1402 mL	2.2804 mL	5.7010 mL
	15 mM	0.1520 mL	0.7601 mL	1.5203 mL	3.8007 mL
	20 mM	0.1140 mL	0.5701 mL	1.1402 mL	2.8505 mL
	25 mM	0.0912 mL	0.4561 mL	0.9122 mL	2.2804 mL
	30 mM	0.0760 mL	0.3801 mL	0.7601 mL	1.9003 mL
	40 mM	0.0570 mL	0.2850 mL	0.5701 mL	1.4252 mL
	50 mM	0.0456 mL	0.2280 mL	0.4561 mL	1.1402 mL

Keywords

MAX-40279

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

MAX-40279

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) MAX-40279

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MAX-40279

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

Protein Tyrosine Kinase Compound Library

Anti-Cancer Compound Library

Reprogramming Compound Library

Orally Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Angiogenesis-Related Compound Library

Anti-Liver Cancer Compound Library

Anti-Prostate Cancer Compound Library

Heterocyclic Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Cytokine Inhibitors Library

Anti-Drug-Resistant Compound Library

Anti-Hematopathy Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Posttranslational Modification Library

Publications Citing Use of MedChemExpress (MCE) MAX-40279

Biologische Aktivität

Chemical Information

Publications (1)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

MAX-40279 Related Classifications

HY-145723 Related Classifications